Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Combination of coronary heart disease and oncopathology

Authors: Rakhmanzhanov A.A., Buziashvili Y.I., Asymbekova E.U., Borbodoeva B.M.

Company:
Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.

DOI: https://doi.org/10.24022/1814-6910-2023-20-2-93-106

UDC: 616.12-008.46-006

Link: Clinical Physiology of Blood Circulaiton. 2023; 2 (20): 93-106

Quote as: Rakhmanzhanov A.A., Buziashvili Y.I., Asymbekova E.U., Borbodoeva B.M. Combination of coronary heart disease and oncopathology. Clinical Physiology of Circulation. 2023; 20 (2): 93–106 (in Russ.). DOI: 10.24022/1814-6910-2023-20-2-93-106

Received / Accepted:  06.04.2023 / 03.05.2023

Download
Full text:  

Abstract

Cardiovascular disease (CVD) is the leading non-neoplastic cause of morbidity and mortality in cancer survivors. СVD account for 27% of all deaths among cancer survivors and 56% of non-cancer deaths. The incidence of both pathologies increases with age, with the average age for diagnosis of common types of malignancies, such as breast, lung and colorectal cancer, being 63–71 years. In addition, obesity and diabetes mellitus, due to their chronic inflammatory nature, lead to the early onset of both ischemic heart disease and neoplasms. Myocardial revascularization methods currently play a significant role in the treatment of patients with coronary artery disease, and the presence of oncological pathology should not limit myocardial revascularization, especially in acute coronary syndrome. Percutaneous coronary interventions (PCI) were strongly associated with lower adjusted odds of major adverse cardiovascular and cerebrovascular events and all-cause mortality in cancer patients compared with the non-cancer population. The choice of stent during PCI in patients with oncological pathologies and coronary artery disease remains a subject of debate. New generation covered stents provide a shorter course of antiplatelet therapy (<_6 months) and allow for safe resumption of tumor treatment in a short time (<_6 months, but after 2 weeks). One of the controversial issues in patients with cancer pathology is the choice of method of myocardial revascularization (PCI or coronary artery bypass grafting (CABG)). In patients with a combination of cancer and coronary artery disease with a good long-term prognosis, CABG may be preferable, and the presence of cancer does not lead to an increase in cardiovascular mortality after CABG. Thus, numerous factors, such as the presence of active progressive cancer, current antitumor therapy and tumor-related comorbidities (fatigue, anemia, thrombocytopenia, cachexia), require the clinician to personalize the management plan for the patient with coronary аrtery disease using a multidisciplinary team consisting of cardiologist, interventional cardiologist and oncologist.

About Authors

  • Alier A. Rakhmanzhanov, Postgraduate; ORCID
  • Yuriy I. Buziashvili, Dr. Med. Sci., Professor, Academician of the Russian Academy of Sciences, Head of Department; ORCID
  • Elmira U. Asymbekova, Dr. Med. Sci., Leading Researcher, Cardiologist; ORCID
  • Baktygul M. Borbodoeva, Cand. Med. Sci., Research Associate, Cardiologist; ORCID

 If you found mistakes, select text and press Alt+A